About: Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.50 (+1.35%)
GYRE NASDAQ Gyre Therapeutics Inc.
Gyre Therapeutics Inc. share price
GYRE price activity
Last Price
$4.500
Change (24hr)
0.06 USD (1.35%)
Volume
106.76K
Volume (4w avg)
-
Open
$4.55
Day Range
$4.50 - $4.65
Previous Close
$4.44
Last Trade
04 Nov, 3:11 pm GMT+0
Delayed
04 Nov, 3:11 pm GMT+0
GYRE price performance
Delayed
04 Nov, 3:11 pm GMT+0
GYRE details
GYRE Market Signals